STOCK TITAN

Trinity Biotech Plc - TRIB STOCK NEWS

Welcome to our dedicated news page for Trinity Biotech Plc (Ticker: TRIB), a resource for investors and traders seeking the latest updates and insights on Trinity Biotech Plc.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Trinity Biotech Plc's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Trinity Biotech Plc's position in the market.

Rhea-AI Summary
Trinity Biotech Plc. (TRIB) has finalized a ratio change for its American depositary shares (ADSs) from 1 ADS representing 4 Class A ordinary shares to 1 ADS representing 20 Class A ordinary shares. The change aims to comply with the $1.00 Nasdaq minimum bid price requirement and maintain its NASDAQ listing.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.92%
Tags
none
-
Rhea-AI Summary
Trinity Biotech Plc. (NASDAQ: TRIB) announced a change in the ratio of American depositary shares (ADSs) to regain Nasdaq compliance and attract more investors. The change, equivalent to a one-for-five reverse split, aims to raise the ADS price and will be effective on February 21, 2024. Shareholders must exchange every five old ADSs for one new ADS.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.57%
Tags
none
-
Rhea-AI Summary
Trinity Biotech plc (TRIB) will present virtually at the Emerging Growth Conference on March 7, 2024. The Company invites investors and analysts to attend its real-time, interactive presentation. Details of the presentation include the date, time, and registration link.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.92%
Tags
conferences acquisition
Rhea-AI Summary
Trinity Biotech Plc. (Nasdaq: TRIB) announced that its New York-based reference laboratory, Immco Diagnostics, has applied for a PLA code for its Early Sjögrens Syndrome Test Panel. This test aims to improve clinical outcomes and reduce the cost burden of care in Sjögrens Syndrome disease management. The company expects the PLA code to be effective in Q3 2024, leading to an optimized market access strategy and improved profitability.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-8.77%
Tags
none
-
Rhea-AI Summary
Trinity Biotech plc (Nasdaq: TRIB) announced Q3 2023 results, including new biosensor technology acquisition, revenue growth from rapid HIV testing, and optimization of diabetes business. The company also entered an amended credit agreement and expects Q4 2023 revenue to be between $13M and $14M.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
37.21%
Tags
earnings
-
Rhea-AI Summary
Trinity Biotech plc (Nasdaq: TRIB) has entered into a non-binding Letter of Intent with Bayer for the launch of a Continuous Glucose Monitoring (CGM) biosensor device in China and India. The partnership with Bayer's subsidiary in China aims to explore an exclusive joint partnership for the launch of a CGM focused biosensor device into the Chinese market. This move is intended to address the significant and rapidly growing diabetes prevalence rate in China and the rising diabetes challenge in India. The intention is to increase affordability and accessibility of diabetes care through the introduction of a low-cost, high-quality CGM device.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
37.21%
Tags
partnership
Rhea-AI Summary
Trinity Biotech plc (Nasdaq: TRIB) has entered into a definitive agreement to acquire the biosensor and Continuous Glucose Monitoring (CGM) assets of Waveform Technologies, Inc. for $12.5 million in cash, 9 million American Depositary Shares (ADSs) of the Company, and additional contingent consideration. The acquisition marks the company's entry into the biosensor market, with a focus on CGM technology. The company plans to redesign and optimize the CGM device for global adoption, targeting key diabetes markets. The acquisition is funded by an amended credit agreement with Perceptive Advisors, providing greater liquidity and lower interest rates. Additional contingent consideration of up to $20 million may be payable based on certain events. The company will host a conference call to discuss the acquisition.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
37.21%
Tags
acquisition
-
Rhea-AI Summary
Trinity Biotech plc (Nasdaq: TRIB) will host an investor call on January 31, 2024, to provide an update on business operations. The call will focus on the company's diagnostic solutions for the point-of-care and clinical laboratory markets.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
37.21%
Tags
conferences
-
Rhea-AI Summary
Trinity Biotech plc (Nasdaq: TRIB) has begun commercial shipments of its new rapid HIV screening test, TrinScreen HIV, to Kenya as part of the country's large HIV screening program. The initial purchase order is for 2.5 million tests, with commitments from sponsors to fund the procurement of all 10 million tests required for 2024. The global HIV screening market is estimated at 150 million tests annually, with the majority in sub-Saharan Africa.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
Rhea-AI Summary
Trinity Biotech plc (Nasdaq: TRIB) announced the promotion of John Gillard to President and Chief Executive Officer, and Des Fitzgerald as Interim Chief Financial Officer. Gillard, an experienced international business executive, aims to leverage his background to drive the company's growth and increase shareholder value.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.08%
Tags
management
Trinity Biotech Plc

Nasdaq:TRIB

TRIB Rankings

TRIB Stock Data

82.15M
69.35M
29.31%
39.29%
0.04%
Surgical and Medical Instrument Manufacturing
Manufacturing
Link
Ireland
Bray

About TRIB

since its formation in 1992, trinity biotech has actively pursued the aim of becoming a leading player in the international diagnostics industry. through a combination of sustained, organic growth and an acquisition-led strategy, the company has assembled an impressive product portfolio and achieved the highest standards of excellence in developing, manufacturing and marketing diagnostic products. the test kits manufactured by trinity biotech are used in the clinical laboratory and point-of-care segments of the diagnostic market to detect infectious diseases, sexually transmitted diseases, autoimmune and haemoglobin disorders, and detect, monitor and control diabetes. the company is also a significant provider of raw materials to the life sciences industry. trinity biotech, which has its headquarters in ireland, employs in excess of 350 people and markets its portfolio of over 400 products to customers in 80 countries around the world. it reaches this worldwide market by combining the